Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors? Participants will * Undergo screening procedures to determine eligibility * Receive study treatments initially every 3 weeks. * Have blood samples taken for routine and research tests * Have other examinations to check heart and lung function, and general health status * Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary. * Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.
Conditions Studied
Interventions
- BIOLOGICAL MGC028
Study Locations (6)
California
- UCSF - Helen Diller Family Cancer Center — San Francisco
Massachusetts
- Dana Farber/Harvard Cancer Center — Boston
Michigan
- South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids
New York
- Icahn School of Medicine at Mt. Sinai — New York
Texas
- South Texas Accelerated Research Therapeutics (START) San Antonio — San Antonio
Utah
- South Texas Accelerated Research Therapeutics (START) Mountain Region — West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2025-02-13 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06723236
The ClinicalTrials.gov registry entry for NCT06723236 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 40 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention — of which MGC028 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06723236 reports 6 study locations spanning 6 distinct geographic areas — top geographies include California, Massachusetts, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06723236 about?
NCT06723236 is a clinical study titled "A Study of MGC028 in Participants With Advanced Solid Tumors". The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally adv...
What is the current status of trial NCT06723236?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2025-02-13. Estimated completion is 2027-04.
What conditions does trial NCT06723236 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Cholangiocarcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, NSCLC Adenocarcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06723236?
The interventions under investigation include: MGC028 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06723236?
This trial is sponsored by MacroGenics, which has 40 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06723236 being conducted?
This trial has 6 study locations across California, Massachusetts, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.